Subtopic Deep Dive
Fungal Infections in Immunocompromised Hosts
Research Guide
What is Fungal Infections in Immunocompromised Hosts?
Fungal infections in immunocompromised hosts refer to invasive mycoses such as aspergillosis, candidiasis, cryptococcosis, and mucormycosis occurring in patients with neutropenia, transplants, chemotherapy, or HIV.
This subtopic covers diagnosis, treatment, and prophylaxis of opportunistic fungal diseases in high-risk groups like hematopoietic stem cell transplant recipients and cancer patients. Key works include EORTC/MSG consensus definitions (de Pauw et al., 2008; 4870 citations) and IDSA guidelines for candidiasis (Pappas et al., 2009; 3192 citations), aspergillosis (Walsh et al., 2008; 2679 citations), and cryptococcosis (Perfect et al., 2010; 2615 citations). Over 20 major guidelines and trials shape standardized approaches.
Why It Matters
Immunocompromised populations, including 1.5 million annual fungal disease deaths globally (Bongomin et al., 2017), face high mortality from aspergillosis and candidiasis without prophylaxis. Voriconazole improved survival over amphotericin B in invasive aspergillosis trials (Herbrecht et al., 2002), while posaconazole reduced infections in neutropenic patients (Cornely et al., 2007). These advances guide transplant centers and oncology units, cutting IFD rates by 50% in some cohorts per registry data.
Key Research Challenges
Diagnostic Uncertainty
Proven IFD requires histopathology, but many cases rely on 'probable' criteria due to low biopsy yields in neutropenic patients (de Pauw et al., 2008). Revised EORTC/MSG definitions (Donnelly et al., 2019; 2568 citations) address imaging and biomarker gaps. Non-culture diagnostics lag for mucormycosis (Cornely et al., 2019).
Antifungal Resistance
Rising azole resistance in Aspergillus and Candida complicates prophylaxis in transplant units (Walsh et al., 2008). Voriconazole efficacy drops in resistant strains post-2002 trials (Herbrecht et al., 2002). Guidelines urge susceptibility testing (Pappas et al., 2009).
Prophylaxis Optimization
Balancing posaconazole benefits against breakthrough zygomycosis in AML patients remains unresolved (Cornely et al., 2007). IDSA guidelines highlight variable efficacy across hosts (Perfect et al., 2010). Registries needed for real-world outcomes.
Essential Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben de Pauw, Thomas J. Walsh, J. Peter Donnelly et al. · 2008 · Clinical Infectious Diseases · 4.9K citations
These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Raoul Herbrecht, David W. Denning, Thomas F. Patterson et al. · 2002 · New England Journal of Medicine · 3.3K citations
In patients with invasive aspergillosis, initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of init...
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas, Carol A. Kauffman, David R. Andes et al. · 2009 · Clinical Infectious Diseases · 3.2K citations
Abstract Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated gu...
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
Felix Bongomin, Sara Gago, Rita Oladele et al. · 2017 · Journal of Fungi · 2.8K citations
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are ...
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
Thomas J. Walsh, Elias Anaissie, David W. Denning et al. · 2008 · Clinical Infectious Diseases · 2.7K citations
Aspergillus species have emerged as an important cause of life-threatening infections in immunocompromised patients. This expanding population is composed of patients with prolonged neutropenia, ad...
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
John R. Perfect, William E. Dismukes, Françoise Dromer et al. · 2010 · Clinical Infectious Diseases · 2.6K citations
Abstract Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Soc...
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly, Sharon Chen, Carol A. Kauffman et al. · 2019 · Clinical Infectious Diseases · 2.6K citations
Abstract Background Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for R...
Reading Guide
Foundational Papers
Start with de Pauw et al. (2008; 4870 citations) for EORTC/MSG definitions, then Herbrecht et al. (2002; 3263 citations) for voriconazole trial, Pappas et al. (2009; 3192 citations) for candidiasis, and Walsh et al. (2008; 2679 citations) for aspergillosis guidelines.
Recent Advances
Study Donnelly et al. (2019; 2568 citations) for updated IFD definitions and Cornely et al. (2019; 1634 citations) for mucormycosis management.
Core Methods
Consensus guidelines (EORTC/MSG, IDSA), RCTs (voriconazole vs. amphotericin), prophylaxis trials (posaconazole), and global prevalence estimates using registries and biomarkers.
How PapersFlow Helps You Research Fungal Infections in Immunocompromised Hosts
Discover & Search
Research Agent uses searchPapers and exaSearch to query 'fungal infections immunocompromised prophylaxis' yielding de Pauw et al. (2008; 4870 citations); citationGraph maps EORTC/MSG definitions to 50+ citing guidelines; findSimilarPapers surfaces Herbrecht et al. (2002) and Cornely et al. (2007) for therapy comparisons.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Herbrecht et al. (2002), then runPythonAnalysis with pandas to compute response rates (53% voriconazole vs. 32% amphotericin B); verifyResponse via CoVe cross-checks claims against Pappas et al. (2009); GRADE grading scores prophylaxis evidence as high-quality from Cornely et al. (2007).
Synthesize & Write
Synthesis Agent detects gaps like mucormycosis prophylaxis post-posaconazole era via contradiction flagging across Cornely et al. (2019) and Donnelly et al. (2019); Writing Agent uses latexEditText and latexSyncCitations to draft guideline summaries citing Walsh et al. (2008), with latexCompile for publication-ready tables and exportMermaid for treatment flowcharts.
Use Cases
"Extract survival stats from voriconazole vs amphotericin aspergillosis trials"
Analysis Agent → readPaperContent (Herbrecht et al., 2002) → runPythonAnalysis (pandas meta-analysis of 391 patients, 52.8% vs 31.7% response) → GRADE high evidence output.
"Draft LaTeX review on IDSA candidiasis guidelines for transplant patients"
Synthesis Agent → gap detection (Pappas et al., 2009) → Writing Agent → latexEditText + latexSyncCitations (10 refs) + latexCompile → PDF with echinocandin dosing table.
"Find code for fungal infection registry analysis"
Research Agent → paperExtractUrls (Bongomin et al., 2017) → paperFindGithubRepo → githubRepoInspect → R script for prevalence modeling output.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'IFD definitions immunocompromised', structures report with EORTC/MSG evolutions (de Pauw 2008 to Donnelly 2019). DeepScan's 7-step chain verifies prophylaxis efficacy: readPaperContent (Cornely 2007) → CoVe → runPythonAnalysis hazard ratios. Theorizer generates hypotheses on resistance patterns from Herbrecht (2002) and Walsh (2008).
Frequently Asked Questions
What defines invasive fungal disease in immunocompromised hosts?
EORTC/MSG criteria classify as 'proven' (histopathology/culture), 'probable' (host factors + markers), or 'possible' (de Pauw et al., 2008; Donnelly et al., 2019).
What are standard treatments for aspergillosis and candidiasis?
Voriconazole first-line for aspergillosis (Herbrecht et al., 2002; Walsh et al., 2008); echinocandins for candidemia (Pappas et al., 2009).
Which papers set guidelines?
IDSA: candidiasis (Pappas 2009), aspergillosis (Walsh 2008), cryptococcosis (Perfect 2010); EORTC/MSG definitions (de Pauw 2008; Donnelly 2019).
What open problems exist?
Antifungal resistance monitoring, mucormycosis diagnostics, and prophylaxis in non-neutropenic hosts lack prospective data (Cornely et al., 2019).
Research Fungal Infections and Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Fungal Infections in Immunocompromised Hosts with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Fungal Infections and Studies Research Guide